| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5583914 | Seminars in Arthritis and Rheumatism | 2017 | 24 Pages |
Abstract
In RCTs, treatment of RA with b-DMARDs or tofacitinib does not increase the risk for malignancies. Generalizability of the differences in the rate of specific malignancies encountered in LTEs requires continuous pharmacovigilance of real-world patients.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
José Ramón Maneiro, Alejandro Souto, Juan J. Gomez-Reino,